Biogen (BIIB) Stock Price, Fundamentals & Analysis

What BIIB does

Biogen (BIIB) is a Healthcare stock in the Drug Manufacturers - General industry, headquartered in Cambridge, United States. The company discovers, develops, manufactures, and delivers therapies across the United States, Europe, Germany, Asia, and internationally. Its portfolio includes treatments for multiple sclerosis such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and OCREVUS; SPINRAZA for spinal muscular atrophy; LEQEMBI for Alzheimer's disease; ZURZUVAE for postpartum depression; RITUXAN for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other conditions; and biosimilars including BENEPALI, IMRALDI, and FLIXABI. With 7,500 employees, Biogen operates as a large-cap company and is part of the S&P 500.

Key numbers explained

• The current price is 227.53 USD, up 0.96% today, with a 52-week range of 135.39 – 229.01 and a 63.7% gain over the past year.
• The trailing P/E ratio of 39.3 shows how much investors pay per dollar of recent earnings; the forward P/E ratio of 13.8 reflects expectations for future earnings.
• Trailing twelve-month earnings per share is 5.79 USD, and the profit margin of 8.3% indicates how much of each revenue dollar becomes profit.
• The dividend yield is 0%, meaning the company currently pays no dividend and retains all earnings.
• Beta of 0.17 suggests the stock has historically moved much less than the overall market.
• The debt-to-equity ratio of 44.3% shows that debt is less than half of shareholders' equity.
• The price-to-book ratio of 1.78 means the market values Biogen at roughly 1.78 times its book value.
• Trailing twelve-month revenue is 10.03 mld. USD, growing 3.4% year over year, with an operating margin of 25.1% and return on equity of 4.6%.

Recent news

Recent headlines highlight investor reactions to Biogen's advancing at-home LEQEMBI pen and kidney disease data, as well as a new kidney trial that has prompted discussion about valuation. Other stories in the feed cover pipeline moves by peers such as Novo Nordisk and broader industry topics like CRM choices among top biopharma companies and Alzheimer's drug stocks for World Alzheimer's Day.

What to watch

Investors tracking Biogen typically watch its pipeline progress in neurology and immunology, regulatory decisions for key products, and how its valuation multiples compare with peers such as Pfizer (PFE), Bristol Myers Squibb (BMY), and Zimmer Biomet (ZBH). Broader factors include healthcare policy changes, currency effects on international sales, and how its beta of 0.17 interacts with market swings.